1. Introduction

Synthetic biology is an emerging branch of biotechnology that combines genetic engineering, molecular biology, computational science and biological systems engineering to design or modify living organisms for scientific, medical, agricultural and industrial purposes.

In Morocco, synthetic biology research funding governance involves the legal and institutional mechanisms through which public authorities, universities, research institutions, private investors and international organisations finance biotechnology research.

The regulation of research funding is important because synthetic biology can generate significant benefits, including:

Development of vaccines and advanced medicines.

Production of biofuels and environmentally sustainable materials.

Improvement of drought-resistant and salt-tolerant crops.

Development of industrial microorganisms.

Protection of biodiversity and agricultural resources.

Advancement of genomic and diagnostic technologies.

However, research funding also creates legal risks involving biosafety, environmental protection, misuse of genetic technologies, intellectual property, research ethics, public accountability and the equitable distribution of scientific benefits.

An important legal distinction: Morocco does not appear to have a single comprehensive statute exclusively regulating synthetic biology research funding. Its governance must therefore be understood through the interaction of general research, biotechnology, environmental, biosafety, public-finance and intellectual-property rules.

2. Constitutional and statutory framework

A. Constitution of Morocco, 2011

The Constitution provides the foundation for state-supported scientific research.

Important provisions include:

Article 25: Protects freedom of scientific and technical research.

Article 26: Requires public authorities to support scientific and technical research through appropriate means.

Article 27: Guarantees access to information held by public authorities, subject to lawful restrictions.

Article 35: Recognises property rights, economic freedom and sustainable development while protecting natural resources.

Article 36: Requires the prevention and punishment of financial misconduct involving public institutions and public funds.

These provisions establish that public funding for synthetic biology should promote scientific advancement while respecting transparency, environmental sustainability and financial accountability.

BDJ

B. Law No. 28-13 of 2015 on Biomedical Research

This is particularly important when synthetic biology research involves human participants, human biological materials, gene therapy or experimental medical products.

Its principal requirements include:

Prior ethical and scientific examination of biomedical research proposals.

Protection of research participants.

Assessment of expected benefits and foreseeable risks.

Appropriate qualifications of investigators.

Adequate technical and institutional research facilities.

Regulatory authorisation where required.

Article 22 requires the research sponsor to submit the project and protocol to the competent regional committee for a reasoned opinion.

Article 27 establishes conditions for authorising biomedical research, including favourable committee review and a proportionate relationship between risks and expected benefits.

Article 24 imposes institutional and facility requirements, including particular restrictions on research involving industrially manufactured gene-therapy and cell-therapy medicines.

Ma Loi+2

Legal significance: Public funding cannot be treated as permission to conduct a biomedical experiment. A funded project must independently satisfy applicable ethical, institutional and regulatory requirements.

C. Law No. 11-03 on Environmental Protection and Enhancement

This law is relevant where synthetic biology research involves genetically modified microorganisms, engineered organisms, biological waste or environmental release.

Funding institutions should consider:

Environmental risk assessment.

Prevention of biological contamination.

Protection of ecosystems and biodiversity.

Safe management of laboratory waste.

Environmental responsibility for funded projects.

The Ministry of Health's official regulatory listing identifies Law No. 11-03 as part of Morocco's environmental and public-health legal framework.

sante.gov.ma+1

D. Law No. 28-00 on Waste Management

Laboratories receiving public or private funding must consider applicable waste-management requirements, particularly when their research generates hazardous biological, chemical or pharmaceutical waste.

Funding agreements should allocate responsibility for waste treatment, storage, transportation and disposal.

E. Law No. 36-15 on Water

Where synthetic biology projects involve industrial fermentation, wastewater, microbial treatment or biological production systems, water-resource protection and applicable discharge requirements become relevant.

F. Law No. 59.24 on Higher Education and Scientific Research

Morocco's newer higher-education and scientific-research legislation is also relevant to the institutional governance of research funding.

The legislation provides for accreditation of research centres, structures and infrastructure. Its Article 100 addresses accreditation requirements for scientific research institutions and facilities.

This is important because a research grant should be administered through an institution that satisfies the applicable legal and accreditation requirements.

Eastlaws

3. Institutional governance of synthetic biology research funding

The governance structure involves several public and research institutions.

Morocco established a National Biosafety Committee through Circular No. 5/2005 of 12 April 2005. Its role involves coordination among relevant government departments and other stakeholders on biosafety matters.

Morocco+1

The distinction between scientific funding approval and biosafety authorisation is important: an institution's decision to finance research does not automatically authorise the import, handling, release or commercialisation of a genetically modified organism.

4. Biosafety and the Cartagena Protocol

Morocco ratified the Cartagena Protocol on Biosafety on 25 April 2011. It entered into force for Morocco on 24 July 2011.

The Protocol is important because it addresses the safe handling, transfer and use of living modified organisms that may affect biodiversity and human health.

Biosafety Clearing-House+1

Its relevance to funding governance includes:

Risk assessment before potentially hazardous activities.

Biosafety capacity-building.

Safe handling and transportation of biological materials.

Monitoring of environmental effects.

International cooperation and information exchange.

Prevention of accidental or unauthorised environmental release.

The Moroccan regulatory gap

Morocco's official biodiversity information reports that a comprehensive national law governing living modified organisms has not been established in the framework described by its biosafety materials. The country has relied on indirect legislation, administrative measures and its biosafety institutions.

An agricultural circular dated 11 August 1999 restricts the introduction of products derived from living modified organisms. The National Biosafety Committee was established through Circular No. 5/2005.

Morocco+1

This creates an important distinction between conventional laboratory research and research involving genetically modified organisms.

For example, a university grant for computational modelling of synthetic DNA does not necessarily create the same regulatory risks as a grant for engineering microorganisms and conducting experiments with living modified organisms.

Consequently, funding authorities should classify projects according to their actual biological activities rather than merely their research titles.

5. Legal procedures for allocating synthetic biology research funds

A legally sound funding system should operate through the following stages.

Stage 1: Research proposal submission

Researchers should submit:

Scientific objectives.

Research methodology.

Institutional affiliation.

Proposed budget.

Expected scientific and social benefits.

Biological materials to be used.

Potential biosafety and environmental risks.

Intellectual-property arrangements.

Stage 2: Scientific evaluation

Independent experts should assess:

Scientific originality.

Research feasibility.

Technical capacity.

Researcher qualifications.

Availability of laboratory infrastructure.

Potential contribution to Moroccan development.

Stage 3: Ethical and biosafety assessment

Projects involving human participants or biomedical interventions must comply with Law No. 28-13.

Projects involving genetically modified organisms should receive appropriate biosafety scrutiny, taking account of the Cartagena Protocol and applicable Moroccan administrative restrictions.

Stage 4: Financial approval

Funding authorities should verify:

Availability of public funds.

Eligibility of research institutions.

Reasonableness of expenditure.

Procurement compliance.

Absence of undisclosed conflicts of interest.

Appropriate financial controls.

Stage 5: Grant agreement

The funding agreement should specify:

Research objectives and deliverables.

Payment schedules.

Permitted expenditure.

Reporting obligations.

Biosafety conditions.

Ownership of intellectual property.

Publication rights.

Audit and inspection rights.

Suspension and recovery provisions.

Stage 6: Monitoring and final audit

Funding authorities should monitor expenditure and scientific progress throughout the project.

Where there is evidence of misuse, falsification of research results, unauthorised biological experimentation or diversion of public funds, the responsible institution should consider suspension, investigation and recovery of funds under the applicable legal framework.

6. Intellectual property and ownership of research outcomes

Synthetic biology research can generate valuable intellectual property, including:

Engineered microorganisms.

Synthetic genetic sequences.

Novel biological production methods.

Diagnostic technologies.

Research software.

Industrial biotechnology processes.

New pharmaceutical applications.

Morocco's Law No. 17-97 on the Protection of Industrial Property, as amended, provides an important framework for patents and related industrial-property rights.

Research funding agreements should establish whether intellectual property belongs to the university, the researcher, a commercial partner or another legally entitled institution.

They should also address:

Patent ownership and inventorship.

Commercialisation rights.

Licensing arrangements.

Access to research materials.

Publication and confidentiality.

Rights arising from international research partnerships.

Protection of biological resources and associated traditional knowledge.

A public grant should not automatically result in unrestricted private ownership of every research outcome. Ownership and exploitation must follow applicable law and the relevant funding agreement.

7. Transparency, corruption prevention and financial accountability

Publicly funded synthetic biology research requires strong financial governance.

The constitutional principles reflected in Articles 27 and 36 support transparency and accountability in the use of public funds.

Key safeguards include:

A. Competitive grant allocation

Funding decisions should use published eligibility criteria and objective scientific evaluation.

B. Conflict-of-interest disclosure

Researchers and reviewers should disclose financial relationships with biotechnology companies, pharmaceutical manufacturers and commercial research partners.

C. Independent auditing

Research institutions should maintain expenditure records and permit appropriate financial audits.

D. Procurement controls

Laboratory equipment, genetic sequencing services, chemicals and biological materials purchased using public money should comply with applicable public procurement rules.

E. Performance-based funding

Further funding may be linked to scientific progress, regulatory compliance, financial reporting and achievement of agreed milestones.

F. Whistleblower protection

Institutions should establish appropriate procedures for reporting research misconduct, financial irregularities and biosafety violations.

8. International funding and cross-border research cooperation

Moroccan synthetic biology research may receive funding from international universities, development agencies, research foundations and biotechnology companies.

International funding arrangements create additional legal questions:

Which country's law governs the grant agreement?

Who owns jointly developed inventions?

Can research materials be transferred abroad?

Who is responsible for biosafety incidents?

How are research participants protected?

Can foreign funders access genetic or biological data?

What happens when the foreign funder terminates the project?

International funding should not exempt a Moroccan research institution from domestic regulatory obligations.

The Cartagena Protocol is particularly relevant where international cooperation involves living modified organisms.

Funding agreements should also specify the responsibility for obtaining any necessary import, export, research, ethical and institutional approvals.

9. Relevant case laws and judicial principles

There is an important limitation in the Moroccan case-law position: I could not identify a reported Moroccan judgment specifically concerning the allocation, misuse or judicial review of funding for synthetic biology research.

Nevertheless, several international judicial decisions provide useful legal principles for interpreting Morocco's regulatory challenges. These decisions are comparative authorities, not binding Moroccan precedents.

A. Diamond v. Chakrabarty (1980), 447 U.S. 303

The United States Supreme Court recognised that a genetically engineered microorganism could qualify as patentable subject matter.

Relevance to Morocco:

Publicly funded research may produce commercially valuable inventions.

Funding agreements should establish ownership of inventions.

Patent protection can encourage private-sector investment.

Research funding should distinguish scientific discovery from commercial exploitation.

B. Association for Molecular Pathology v. Myriad Genetics, 569 U.S. 576 (2013)

The US Supreme Court held that naturally occurring DNA is not patentable merely because it has been isolated, while synthetically created complementary DNA could qualify for patent protection, subject to applicable patent requirements.

Relevance to Morocco:

This judgment illustrates why public research funding agreements must distinguish between naturally occurring biological materials and genuinely inventive technological developments.

It also raises questions about equitable access to publicly supported genetic technologies.

C. Confédération paysanne v Premier ministre (2018), Case C-528/16

The Court of Justice of the European Union examined whether organisms obtained through newer mutagenesis techniques fall within the EU genetically modified organism regulatory framework.

The judgment is important for understanding the relationship between technological innovation and biosafety regulation.

Relevance to Morocco:

It demonstrates the importance of assessing new gene-editing and synthetic biology techniques carefully when determining whether research requires biosafety controls.

D. Monsanto SAS v Président de l'Assemblée nationale — French GMO regulatory litigation

French litigation concerning genetically modified organisms illustrates the importance of scientific risk assessment, regulatory oversight and precautionary environmental protection.

Its comparative significance is that public funding should not be treated as a substitute for environmental and biosafety authorisation.

E. WTO EC — Approval and Marketing of Biotech Products (2006)

The WTO dispute concerned European Community measures affecting the approval and marketing of biotechnology products.

The dispute illustrates the importance of scientific evidence, regulatory procedures and international trade obligations.

Relevance to Morocco:

Moroccan funding programmes supporting agricultural synthetic biology should consider international biosafety and trade requirements when research is intended for eventual commercialisation or export.

10. Principal legal challenges in Morocco

Several difficulties affect the development of an effective synthetic biology funding framework.

A particularly significant issue is the relationship between research funding and biosafety regulation.

A project may receive financial approval from a university but still face restrictions on particular biological experiments. This can result in delays, financial losses and contractual disputes.

11. Recommendations for reforming Morocco's synthetic biology funding governance

Morocco could strengthen its governance system through the following reforms.

1. Establish a dedicated synthetic biology funding framework

A national framework should identify eligible research activities, funding conditions, institutional responsibilities and regulatory approval requirements.

2. Introduce risk-based funding categories

Research could be classified into:

Category I: Computational and theoretical synthetic biology.

Category II: Non-pathogenic laboratory research.

Category III: Research involving genetically modified microorganisms.

Category IV: Research presenting significant environmental or public-health risks.

Each category should have appropriate financial and biosafety controls.

3. Establish a national synthetic biology research fund

A dedicated funding mechanism could support universities, public laboratories and eligible private research institutions.

4. Strengthen biosafety institutional capacity

The government should support:

Specialist biosafety laboratories.

Independent risk-assessment experts.

Biological containment facilities.

Research inspection systems.

Emergency response mechanisms.

5. Introduce transparent grant allocation

Grant awards should be based on published criteria, independent peer review and documented decisions.

6. Protect public research investments

Public funding agreements should establish reasonable licensing, benefit-sharing and commercialisation conditions.

7. Strengthen international cooperation

Morocco should develop standard contractual safeguards for international research collaborations, including intellectual-property ownership, biological-material transfers, data protection and research accountability.

8. Introduce independent monitoring

An appropriate national oversight mechanism should periodically assess the scientific, financial, ethical and environmental performance of funded research.

12. Hypothetical legal case study

Consider a Moroccan public university receiving government funding to develop genetically engineered microorganisms for producing drought-resistant agricultural products.

The project receives a research grant and purchases laboratory equipment. However, the university begins experiments involving living modified organisms without resolving the applicable biosafety and administrative requirements.

A biological containment incident subsequently occurs.

The following legal questions arise:

Did the university comply with applicable biosafety restrictions?

Did the funding authority adequately assess the proposed research?

Were appropriate laboratory safeguards maintained?

Did the university comply with environmental requirements?

Does the funding agreement permit suspension or recovery of the grant?

Which institution bears responsibility for the incident?

The university's receipt of funding does not establish legal authorisation for the experiment.

Depending on the facts, administrative, civil or other applicable legal consequences may arise. The responsibility of the funding authority would also depend on its statutory duties and actual involvement.

This hypothetical demonstrates why scientific funding approval, ethical approval and biosafety compliance must remain separate but coordinated processes.

13. Conclusion

Regulation of synthetic biology research funding governance in Morocco requires coordination between constitutional protections for scientific research, biomedical research legislation, environmental protection rules, intellectual-property law, public financial accountability and international biosafety obligations.

The Constitution of 2011 provides a foundation for government support of scientific research through Articles 25 and 26. Law No. 28-13 of 2015 establishes important protections for biomedical research participants. Environmental legislation and the Cartagena Protocol provide additional safeguards where research involves living modified organisms and potential environmental risks.

However, the absence of a comprehensive synthetic biology-specific regulatory and funding framework creates challenges concerning institutional accountability, biosafety supervision, grant allocation and intellectual-property ownership.

The central legal principle should be that public funding must facilitate scientific innovation without weakening ethical standards, biosafety obligations, environmental protection or financial accountability.

14. Important legal references

Useful official and legal research sources:

Moroccan Constitution of 2011.

Moroccan Law No. 28-13 on Biomedical Research.

Moroccan environmental legislation.

Cartagena Protocol – Morocco country profile.

Moroccan working group on biodiversity and biosafety.

Moroccan Ministry of Justice legal portal.

Research qualification: The international judgments discussed above are comparative case law. They should not be cited as judgments of Moroccan courts or as binding interpretations of Moroccan funding legislation. Morocco-specific reported judicial decisions directly addressing synthetic biology research grants remain an area requiring further case-law research.